HOXA9 and leukemia: When primary NUP98-HOXA9 AML cells with reduced HoxBlinc were transplanted into mice, the progression of leukemia was delayed, suggesting that HoxBlinc was crucial for the oncogenic transformation driven by the NUP98-HOXA9 fusion.